I am a
Home I AM A Search Login

Papers of the Week


2020 Feb


Dermatol Ther (Heidelb)


10


1

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis.

Authors

Grace E, Goldblum O, Renda L, Agada N, See K, Leonardi C, Menter A
Dermatol Ther (Heidelb). 2020 Feb; 10(1):99-106.
PMID: 31734937.

Abstract

Biologics used to treat moderate-to-severe plaque psoriasis may cause injection site reactions (ISRs) characterized by erythema, edema, itch, and sometimes pain. The Federal Adverse Event Reporting System (FAERS) is a repository of spontaneous post-marketing reports of adverse events (AEs) that are reported to the US Food and Drug Administration (FDA). Our objective was to perform a pharmacovigilance analysis of FAERS reports of ISRs associated with the use of subcutaneously administered biologic products approved to treat moderate-to-severe plaque psoriasis.